GemPharmatech (SH:688046) Zhong Zheng Wang·2025-03-27 09:18Core Viewpoint - The company aims to enhance employee engagement and competitiveness through equity incentive plans, promoting long-term and sustainable development [1][2] Group 1: Employee Stock Ownership Plan - The 2025 Employee Stock Ownership Plan (draft) will have a maximum of 45 holders, including one senior management member [1] - The plan involves approximately 2.04 million shares, accounting for 0.50% of the total share capital of 410 million shares [1] - The funding sources for the plan will primarily be from employees' legal salaries and self-raised funds, with a duration of 36 months [1] - A reserve of 400,000 shares, representing 19.61% of the total stock in the plan, is set aside to attract and retain talent, pending shareholder approval [1] Group 2: Stock Appreciation Rights Incentive Plan - The 2025 Stock Appreciation Rights Incentive Plan (draft) proposes to grant 546,000 stock appreciation rights to 27 senior management and core personnel, which is about 0.13% of the total share capital [1] Group 3: Strategic Goals and Market Expansion - The company emphasizes establishing a long-term incentive mechanism to attract and retain talent, thereby enhancing employee motivation and promoting sustainable development [2] - The performance indicators for the incentive plans are based on revenue, which is crucial for assessing the company's operational status and market share [2] - The company has successfully formed an overseas sales team of over 40 members, covering key regions such as North America, Asia-Pacific, and Europe [2] - The number of overseas clients is steadily increasing, and the company is gaining familiarity with international markets, which is a core strategic focus [2] - The company expects to maintain good growth in overseas markets over the next 3-5 years [2]